AI-powered CKD drug ISM4808 licensed for kidney disease therapy

By 2025-12-15T08:30:37

Chronic,Kidney,Disease.,3d,Illustration

Insilico Medicine has partnered with TaiGen Biotechnology to exclusively license its AI-designed PHD inhibitor, ISM4808, for the treatment of CKD-related anaemia in Greater China.

Already a member? Sign in

Unlock

Intelligence for the future of drug discovery

By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member